Francesca De Iuliis1, Gerardo Salerno2, Ludovica Taglieri3, Susanna Scarpa4. 1. Experimental Medicine Department, Sapienza University of Rome, Viale Regina Elena 324, 00161, Rome, Italy. francesca.deiuliis@yahoo.it. 2. Experimental Medicine Department, Sapienza University of Rome, Viale Regina Elena 324, 00161, Rome, Italy. sagerardo@libero.it. 3. Experimental Medicine Department, Sapienza University of Rome, Viale Regina Elena 324, 00161, Rome, Italy. ludovica.taglieri@yahoo.it. 4. Experimental Medicine Department, Sapienza University of Rome, Viale Regina Elena 324, 00161, Rome, Italy. susanna.scarpa@uniroma1.it.
Abstract
PURPOSE: Breast cancer is a heterogeneous disease, characterized by various molecular phenotypes that correlate with different prognosis and response to treatments. Taxanes are some of the most active chemotherapeutic agents for breast cancer; however, their utilization is limited, due to hematologic and cumulative neurotoxicity on treated patients. To understand why only some patients experience severe adverse effects and why patients respond and develop resistance with different rates to taxane therapy, the metabolic pathways of these drugs should be completely unraveled. The variant forms of several genes, related to taxane pharmacokinetics, can be indicative markers of clinical parameters, such as toxicity or outcome. METHODS: The search of the data has been conducted through PubMed database, presenting clinical data, clinical trials and basic research restricted to English language until June 2015. RESULTS: We studied the literature in order to find any possible association between the major pharmacogenomic variants and specific taxane-related toxicity and patient outcome. We found that the data of these studies are sometimes discordant, due to both the small number of enrolled patients and the heterogeneity of the examined population. CONCLUSIONS: Among all analyzed genes, only CYP1B1 and ABCB1 resulted the strongest candidates to become biomarkers of clinical response to taxane therapy in breast cancer, although their utilization still remains an experimental procedure. In the future, greater studies on genetic polymorphisms should be performed in order to identify differentiating signatures for patients with higher toxicity and with resistant or responsive outcome, before the administration of taxanes.
PURPOSE:Breast cancer is a heterogeneous disease, characterized by various molecular phenotypes that correlate with different prognosis and response to treatments. Taxanes are some of the most active chemotherapeutic agents for breast cancer; however, their utilization is limited, due to hematologic and cumulative neurotoxicity on treated patients. To understand why only some patients experience severe adverse effects and why patients respond and develop resistance with different rates to taxane therapy, the metabolic pathways of these drugs should be completely unraveled. The variant forms of several genes, related to taxane pharmacokinetics, can be indicative markers of clinical parameters, such as toxicity or outcome. METHODS: The search of the data has been conducted through PubMed database, presenting clinical data, clinical trials and basic research restricted to English language until June 2015. RESULTS: We studied the literature in order to find any possible association between the major pharmacogenomic variants and specific taxane-related toxicity and patient outcome. We found that the data of these studies are sometimes discordant, due to both the small number of enrolled patients and the heterogeneity of the examined population. CONCLUSIONS: Among all analyzed genes, only CYP1B1 and ABCB1 resulted the strongest candidates to become biomarkers of clinical response to taxane therapy in breast cancer, although their utilization still remains an experimental procedure. In the future, greater studies on genetic polymorphisms should be performed in order to identify differentiating signatures for patients with higher toxicity and with resistant or responsive outcome, before the administration of taxanes.
Authors: Dmytro Havrylyuk; Austin C Hachey; Alexander Fenton; David K Heidary; Edith C Glazer Journal: Nat Commun Date: 2022-06-25 Impact factor: 17.694
Authors: Lin-Yu Yu; Jie Tang; Cong-Min Zhang; Wen-Jing Zeng; Han Yan; Mu-Peng Li; Xiao-Ping Chen Journal: Int J Environ Res Public Health Date: 2017-01-12 Impact factor: 3.390